Authors: D. Očadlíková 1; L. Kovářová 1; R. Hájek 1,2; J. Michálek 1,3 Authors‘ workplace: Laboratoř experimentální hematologie a buněčné imunoterapie při oddělení klinické hematologie 1; Interní hematoonkologická klinika 2; I. dětská interní klinika, Fakultní nemocnice Brno 3 Published in: Transfuze Hematol. dnes,11, 2005, No. 3, p. 104-109. Category: Comprehensive Reports, Original Papers, Case Reports
Backgrounds: Multiple myeloma is an incurable hematological disease. High-dose chemotherapy including autologous stem cell transplantation is recently considered a standard therapy for myeloma. Unfortunately, a relapse of the disease is inevitable. Therefore, new approaches such as immunotherapy have been considered recently. A specific activation of cytotoxic T cells can be reached using dendritic cells loaded with tumor-specific antigen. Catalytic subunit of telomerase hTERT and an HLA-A2-specific nonapeptide derived from hTERT can be used.
Design and subjects: Activation and identification of myeloma-specific T cells from healthy HLA-A2 blood donors has been tested in an in vitro study using hTERT-derived nonapeptide as a tumor-specific antigen.
Methods and results: T cells and dendritic cells were obtained from peripheral blood. T cells were repeatedly stimulated with hTERT nonapeptide - loaded dendritic cells. Activated myeloma-specific T cells produced interferon gamma and were evaluated by flow cytometry.
Conclusion: This study demonstrates feasibility of an in vitro identification of tumor-specific T cells that can be used in myeloma therapy.
Key words: Multiple myeloma, immunotherapy, interferon gamma, catalytic subunit of telomerase
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
